Compare Kyndryl Holdings Inc (KD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Kyndryl Holdings Inc trades at $12.04 (market cap $2.69B), while State Street SPDR S&P Biotech ETF trades at $154.06. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| KD | XBI | |
|---|---|---|
Market Cap | $2.69B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $39.47 | $164.28 |
52-Week Low | $10.59 | $85.16 |
Enterprise Value | $5.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl Holdings (KD) trades at $12.195, up 0.37% on the day, with a neutral technical signal and bullish moving averages. The company reported revenue of $15.06B in 2025, turning profitable with net income of $252M after years of losses. Recent news includes leadership changes, partnership expansions with Microsoft and AWS, and multiple law firm investigations into corporate governance, creating mixed sentiment.
The outlook is cautiously optimistic with a consensus price target of $14.00, implying 15% upside, but risks include ongoing legal probes, volatile earnings history with recent misses, and high debt levels. Improved cash flow and strategic alliances support growth, yet investor confidence remains tempered by governance concerns and margin pressures.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
